Financial reports
Current reports
8-K
Bankruptcy or Receivership
24 Feb 23
8-K
Submission of Matters to a Vote of Security Holders
8 Feb 23
8-K
LexaGene Provides Update on BioPharma Sector
8 Feb 23
8-K
Regulation FD Disclosure
18 Jan 23
8-K
BioPharma Engages LexaGene in Second Feasibility Study
16 Dec 22
8-K
Regulation FD Disclosure
7 Dec 22
8-K
LexaGene Successfully Completes Statement of Work for BioPharma Company
22 Nov 22
8-K
LexaGene Closes Secured Convertible Note Transaction
1 Nov 22
8-K
Regulation FD Disclosure
27 Oct 22
8-K
Entry into a Material Definitive Agreement
26 Oct 22
Registration and prospectus
S-8
Registration of securities for employees
9 Feb 23
D
$1.60 mm in debt / options / securities to be acquired, sold $1.60 mm, 1 investor
16 Nov 22
10-12G/A
Registration of securities (amended)
9 Aug 22
10-12G
Registration of securities
28 Jun 22
D/A
$11.47M in equity / options / securities to be acquired, sold $5M, 1 investor
28 Feb 22
D
$8.13M in equity / options / securities to be acquired, sold $3.54M, 1 investor
17 Feb 22
D/A
$8.13M in equity / options / securities to be acquired, sold $3.54M, 1 investor
16 Feb 22
D
$1.66M in equity / options / securities to be acquired, sold $1.01M, 4 investors
5 Oct 20
D
$2.44M in equity / options / securities to be acquired, sold $998.83K, 19 investors
7 Nov 19
D
$265.84K in equity / options / securities to be acquired, sold $115.2K, 15 investors
15 Apr 19